

**PATENT**  
Docket No. BZL-003D3  
(13651/003)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANTS:	Neil H. Bander	GROUP NO.:	1643
SERIAL NO.:	09/357,704	EXAMINER:	Stephen L. Rawlings
FILING DATE:	July 20, 1999	CONF. NO.:	9622
TITLE:	TREATMENT AND DIAGNOSIS OF PROSTATE CANCER		

**TERMINAL DISCLAIMER**

In accordance with 37 C.F.R. § 3.73(b), I, Brian J. Kelly, state that I am a representative authorized to sign on behalf of Cornell Research Foundation, Inc., identified below as the assignee of the entire right, title and interest in and to the above-identified patent application, U.S. Application No. 09/357,704. I, along with legal counsel, have reviewed all the evidentiary documents accompanying or referred to in the instant Terminal Disclaimer and certify that, to the best of my knowledge and belief, title to the above-identified application is in the name of Cornell Research Foundation, Inc.

Cornell Research Foundation, Inc. of 395 Pine Tree Road, Suite 310, Ithaca, New York, 14850 is the assignee of the entire right, title and interest in and to U.S. Application No. 09/357,704 by virtue of the Assignment recorded in the United States Patent and Trademark Office at Reel 023266, Frame 0948, on September 22, 2009 by the inventor in this application to Cornell Research Foundation, Inc.

Cornell Research Foundation, Inc. hereby waives and disclaims the terminal part of any patent granted on the above-identified application which would extend beyond the full statutory term (which may be longer than seventeen (17) years) of U.S. Patent No. 7,514,078, which issued on April 7, 2009, and hereby agrees that any patent so granted on U.S. Application No. 09/357,704 shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to U.S. Patent No. 7,514,078, this agreement to run with any patent granted on U.S. Application No. 09/357,704 and to be binding upon the Assignee, its successors or assigns.

Cornell Research Foundation, Inc. does not disclaim any terminal part of the term of any patent granted on U.S. Application No. 09/357,704 prior to the expiration date of the full statutory term of U.S. Patent No. 7,514,078, in the event that any said patent expires for failure to pay a maintenance fee, is held unenforceable, is found invalid, is statutorily disclaimed in whole, or terminally disclaimed under 37 C.F.R. 1.321(a), has all claims canceled by a reexamination certificate, or is otherwise terminated prior to expiration of its statutory term as presently shortened by any terminal disclaimer, if any, except for the separation of legal title stated above.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made in the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Cornell Research Foundation, Inc.

By: Brian Kelly  
Name: Brian J. Kelly, Vice President

Date: Sept. 23, 2009